The Application of microRNAs in Papillary Thyroid Cancer: A Bibliometric and Visualized Analysis
Tinghua Zhang,Bo Yuan,Shaofu Yu
DOI: https://doi.org/10.2147/ijgm.s487239
IF: 2.145
2024-10-16
International Journal of General Medicine
Abstract:Tinghua Zhang, 1 Bo Yuan, 2 Shaofu Yu 3 1 Department of Clinical Laboratory, the Second People's Hospital of Huaihua City, Huaihua, Hunan, People's Republic of China; 2 Department of Clinical Laboratory, Southern University of Science and Technology Hospital, Guangdong, Shenzhen, People's Republic of China; 3 Department of Clinical Pharmacy, the Second People's Hospital of Huaihua, Huaihua, Hunan, People's Republic of China Correspondence: Shaofu Yu, Department of Clinical Pharmacy, the Second People's Hospital of Huaihua, Huaihua, Hunan, People's Republic of China, Tel +86-13974531958, Email Objective: Thyroid cancer is the most common malignant endocrine tumor, with papillary thyroid carcinoma (PTC) being the most prevalent type, accounting for 85% of thyroid cancer cases. Here, we conducted a bibliometric analysis of the literature in the field of microRNAs in PTC research to demonstrate current trends and research hotspots, and present a visual map of past and emerging trends. Methods: We searched the Web of Scientific Core Collection (WoSCC) database for publications from 1999 to 2023 centered on this field. Next, we employed visualization tools such as VOSviewer, CiteSpace, and Microsoft Excel 2019 to present co-occurrence and co-citation analyses, trends, hotspots, and visual representations of contributions from authors, institutions, journals, and countries/regions. Results: The bibliometric analysis encompassed the period from 1999 to 2023, with 994 papers from 54 countries/regions. The country with the most publications and highest total citations was the People's Republic of China, but the United States held the highest average citation rate. Among the top ten productive institutions, the Ohio State University (Ohio State Univ) was the most prominent contributor to this field. The JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (J Clin Endocrinol Metab) ranked first in terms of citation counts and average citations among the top ten productive journals. In terms of keywords, "circular RNAs", "promotes", and "progression" have become prominent research areas. Conclusion: This study elucidates current trends, hotspots, and emerging frontiers in miRNA research within PTC, and provides new insights and guidance for future identification of new PTC biomarkers and clinical trials. Keywords: microRNAs, papillary thyroid cancer, bibliometric, VOSviewer, CiteSpace Thyroid cancer is the most common malignant tumor in endocrine tumors. According to pathological classification, it can be divided into papillary thyroid carcinoma (PTC), medullary thyroid carcinoma, follicular thyroid carcinoma, and undifferentiated thyroid carcinoma. The most malignant is undifferentiated thyroid carcinoma, while medullary thyroid carcinoma has moderate malignancy. PTC and follicular thyroid carcinoma have lower malignancy levels. PTC, follicular thyroid carcinoma, and undifferentiated thyroid carcinoma originate from follicular cells, while medullary thyroid carcinoma originates from non-follicular cells. 1 PTC is the most common type of thyroid cancer, 2 accounting for 85% of thyroid cancer cases. 3 In recent years, the incidence of PTC has been rapidly increasing in many countries worldwide. 4 Due to its highly invasive and metastatic nature, the incidence of PTC is increasing faster than other solid tumors globally. 5 The rising incidence of PTC has raised significant concerns in global public health. Most well-differentiated thyroid cancer patients are asymptomatic and are usually discovered during routine physical examinations or incidentally during imaging studies. For tumors smaller than or equal to 1 cm, surgery may not be necessary; for tumors larger than 1 cm, surgery is usually required regardless of lymph node involvement. 6 After surgery, PTC patients have a longer survival time, with a five-year relative survival rate of approximately 98.5% in the United States. 6 Despite advances in the diagnosis and treatment of thyroid cancer, the increasing detection rate of PTC due to advancements in diagnostic technologies, there is still room for improvement in the accuracy of screening and diagnosis. The common methods for early screening and diagnosis of thyroid cancer are ultrasound and fine-needle aspiration biopsy (FNA). 3 FNA is the gold standard for diagnosing thyroid cancer, but it may not always provide a complete picture of the cancer, leading to misdiagnosis. Furthermore, it is a complex and invasive procedure. Due to the complexity and stealthiness of thyroid cancer, there is a need to explore new biomarkers, with microRNAs (miRNAs) being one of the promising research targets. Ident -Abstract Truncated-
medicine, general & internal